Ziopharm Oncology Inc (ZIOP) 3.37 $ZIOP
Emergent BioSolutions Gains on Trial News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:10PM CDT
Emergent BioSolutions is looking to expand BioThrax's label.
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:40AM CDT
Biogen/Sobi reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Gentiva Health Slumps: GTIV Falls 6.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:33AM CDT
Shares of Gentiva Health fell over 6% on the day. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $8.5 to $9.5 in the past one-month time frame. This home health services provider company has seen a flat track record when it comes to current year estimate revisions.
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer
GlobeNewswire - Tue Apr 08, 11:51AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response.
ZIOPHARM Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:50PM CDT
ZIOPHARM's track record is pretty impressive with the company delivering positive surprises in the last couple of quarters.
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Strength Seen in ZIOPHARM Oncology (ZIOP): Stock Up 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:04AM CDT
ZIOPHARM Oncology, Inc. was a big mover last session, as the company saw its shares rise nearly 12% on the day.
ZIOPHARM (ZIOP) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:45AM CDT
ZIOPHARM (ZIOP) Shares March Higher, Can It Continue?
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
ZIOPHARM Oncology to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
GlobeNewswire - Thu Mar 20, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 21 Annual Future Leaders in the Biotech Industry Conference on Friday, March 28th, 2014 at 3:00 p.m. ET at the Millennium Broadway Hotel in New York City.
Market Research Report: Cancer Gene Therapy Market Analysis
M2 - Thu Mar 20, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59s3c/cancer_gene) has announced the addition of the "Cancer Gene Therapy Market Analysis" report to their offering. The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines. Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer. Cancer Gene Therapy Report Highlights & Findings: - Highest Number of Drugs in Preclinical Stage: 37 - Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100 - Significance of Oncology Therapeutics in Gene Therapy - Current Applications of Gene Therapy to Cancer Treatment - Favorable Parameters for Cancer Gene Therapy - Issued Involved with Application of Gene Therapy in Cancer Patients - Regulatory Scenario for Gene Therapy Market - Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications Companies Mentioned - Advantagene - BioCancell - Celgene - Cell Genesys - Epeius Biotechnologies - GenVec - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/h5...ancer_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Investors' Radars Failed to Catch ZIOPHARM (ZIOP), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:51AM CDT
ZIOPHARM has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Emergent BioSolutions Gains on Trial News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:10PM CDT
Emergent BioSolutions is looking to expand BioThrax's label.
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:40AM CDT
Biogen/Sobi reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Gentiva Health Slumps: GTIV Falls 6.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:33AM CDT
Shares of Gentiva Health fell over 6% on the day. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $8.5 to $9.5 in the past one-month time frame. This home health services provider company has seen a flat track record when it comes to current year estimate revisions.
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer
GlobeNewswire - Tue Apr 08, 11:51AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response.
ZIOPHARM Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:50PM CDT
ZIOPHARM's track record is pretty impressive with the company delivering positive surprises in the last couple of quarters.
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Strength Seen in ZIOPHARM Oncology (ZIOP): Stock Up 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:04AM CDT
ZIOPHARM Oncology, Inc. was a big mover last session, as the company saw its shares rise nearly 12% on the day.
ZIOPHARM (ZIOP) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:45AM CDT
ZIOPHARM (ZIOP) Shares March Higher, Can It Continue?
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
ZIOPHARM Oncology to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
GlobeNewswire - Thu Mar 20, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 21 Annual Future Leaders in the Biotech Industry Conference on Friday, March 28th, 2014 at 3:00 p.m. ET at the Millennium Broadway Hotel in New York City.
Market Research Report: Cancer Gene Therapy Market Analysis
M2 - Thu Mar 20, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59s3c/cancer_gene) has announced the addition of the "Cancer Gene Therapy Market Analysis" report to their offering. The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines. Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer. Cancer Gene Therapy Report Highlights & Findings: - Highest Number of Drugs in Preclinical Stage: 37 - Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100 - Significance of Oncology Therapeutics in Gene Therapy - Current Applications of Gene Therapy to Cancer Treatment - Favorable Parameters for Cancer Gene Therapy - Issued Involved with Application of Gene Therapy in Cancer Patients - Regulatory Scenario for Gene Therapy Market - Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications Companies Mentioned - Advantagene - BioCancell - Celgene - Cell Genesys - Epeius Biotechnologies - GenVec - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/h5...ancer_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Investors' Radars Failed to Catch ZIOPHARM (ZIOP), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:51AM CDT
ZIOPHARM has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
